Live
- Sudanese army recaptures capital of Sinnar State in central Sudan
- Kishkindha Kaandam Review: Some movies prove not to compromise in having a good cinematic experience and this is one of them
- Son-rise: Hemant Soren grows taller as tribal leader, makes father proud
- ISL 2024-25: 10-man NorthEast United FC hold on to take three points vs Punjab FC
- BGT 2024-25: Jaiswal’s application, commitment to form a partnership was so impressive, says Gilchrist
- BGT 2024-25: Personally, I am very happy with my performance, says Harshit Rana
- Pakistan's Lahore remains world's most polluted city despite light drizzle
- Asha Nautiyal retains Kedarnath for BJP, to be back as MLA after 12 years
- India leads world in science, innovation research: Minister
- Flash flood in Indonesia's South Tapanuli claims two lives
Dr Reddy's net zooms 30% to Rs 992 cr in Q2
Dr Reddy’s net zooms 30% to Rs 992 cr in Q2
Drug maker has posted a net profit of `762.3 crore for the corresponding period in FY21
Hyderabad: Drug major Dr Reddy's Laboratories on Friday reported a 30 per cent jump in its consolidated net profit to Rs 992 crore for the quarter ended September 30, 2021, on account of other income and robust sales in all markets.
The company had posted a net profit of Rs 762.3 crore for the corresponding period of the previous financial year, Dr Reddy's Laboratories said in a press release.Its consolidated revenue during July-September 2021 stood at Rs 5,763.2 crore. It was Rs 4,896.7 crore in the year-ago period, it added.
"I am pleased with the improvement in the financial performance across our businesses.
While we continue to strengthen our core businesses of genericsand APls (active pharmaceutical ingredients), we are also making investments in our long-term growth drivers and deeper innovation capabilities," Dr Reddy'sLaboratories co-Chairman and Managing Director G V Prasad said.Under the Covid-19 products basket, the drug maker launched Sputnik V vaccine, remdesivir, avigan and 2-deoxy-D-glucose (2-DG) till now.
